GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Gilead Sciences, Inc. (GILD) [hlAlert]

Rating:
Hold GILD
up 34.72 %

Gilead Sciences, Inc. (GILD) upgraded to Hold by Morgan Joseph

Posted on: Tuesday,  May 25, 2010  8:25 AM ET by Morgan Joseph

Morgan Joseph rated Hold Gilead Sciences, Inc. (NASDAQ: GILD) on 05/25/2010. Previously Morgan Joseph rated Sell Gilead Sciences, Inc. (NASDAQ: GILD) on
02/22/2010., when the stock price was $24.31. Since then, Gilead Sciences, Inc. has lost 25.78% as of 05/25/2010's recent price of $18.04.
If you would have followed the previous Morgan Joseph's recommendation on GILD, you would have gained 34.72% of your investment in 92 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/25/2010 8:25 AM Hold
None
18.04
as of 12/31/2010
1 Week   
1 Month   
3 Months   
1 YTD up  38.11 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/22/2010 8:25 AM Sell
None
24.31 18.50
4/22/2009 8:25 AM Buy
None
23.50 28.50
12/9/2008 8:25 AM Hold
None
22.90

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy